<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060189</url>
  </required_header>
  <id_info>
    <org_study_id>UTI Pilot Study</org_study_id>
    <nct_id>NCT01060189</nct_id>
  </id_info>
  <brief_title>Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery</brief_title>
  <official_title>Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery With Cardiopulmonary Bypass: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic&#xD;
      transfusions. The extensively studied antifibrinolytic drug aprotinin is efficacious but&#xD;
      expensive, and has been proved to link to higher risks of serious side effects including&#xD;
      renal problems, myocardial events, and strokes in patients undergoing CABG. After the&#xD;
      secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac&#xD;
      surgery took place. An effective and secure hemostatic agent is badly needed. Ulinastatin,&#xD;
      urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide&#xD;
      inhibition spectrum, including plasmin. Limited studies offered clues to its antifibrinolytic&#xD;
      effect. Tranexamic acid has been applied for years with convinced efficacy and safety. The&#xD;
      objective of the study is to evaluate the hemostatic effect of ulinastatin and tranexamic&#xD;
      acid in cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2008</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative blood loss</measure>
    <time_frame>Postoperatively</time_frame>
    <description>Defined as the total volume of chest drainage postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reexploration for bleeding</measure>
    <time_frame>Postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major bleeding</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Major bleeding is defined according to the CURE study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of allogeneic erythrocytes</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Rate of exposure and volume of allogeneic erythrocytes transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of fresh frozen plasma (FFP)</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Rate of exposure and volume of FFP transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of allogeneic platelets</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Rate of exposure and volume of allogeneic platelets transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital postoperatively</measure>
    <time_frame>Postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">426</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>Ulinastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50ml saline solution before skin incision; 50ml saline solution after neutralization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulinastatin</intervention_name>
    <arm_group_label>Ulinastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atrial or ventricular septum defect patients requiring cardiac surgery with CPB&#xD;
&#xD;
          -  Rheumatic or recessive valvular patients requiring valvular repair or replacement with&#xD;
             CPB&#xD;
&#xD;
          -  Coronary artery disease patients requiring coronary revascularization surgery with CPB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-primary cardiac surgery&#xD;
&#xD;
          -  Definite liver or renal dysfunction&#xD;
&#xD;
          -  Disorder in coagulation function&#xD;
&#xD;
          -  Allergy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Disabled in spirit or law&#xD;
&#xD;
          -  Fatal conditions such as tumour&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihuan Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>February 2, 2019</last_update_submitted>
  <last_update_submitted_qc>February 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Associated Professor and Vice Chair of department of anesthesiology, Fuwai Hospital, NCCD, PUMC &amp; CAMS</investigator_title>
  </responsible_party>
  <keyword>ulinastatin</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery procedures</keyword>
  <keyword>hemostasis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

